|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Genfit SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated ... Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a ... Global NASH (Non –Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) Executive Summary Progressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH Drugs The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population ... Nonalcoholic Steatohepatitis: KOL Insight ... , Genfit's PPAR alpha/delta agonist, GFT505 and Gilead's Simutuzumab. Others vying ... differentiators could Genfit exploit for GFT505, its PPAR alpha/delta agonist ... NASH: KOL Insight [2017] Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years? Allergan/Tobira’s cenicriviroc and Gilead’s ... Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2028 This report can be delivered to the clients within 7-10 Business Days DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & ... Physician Views: How Have Recent Data, Study Design Events Shaped Doctors’ Thinking on Lead NASH Agents ... late March that its GFT505 missed the study’s primary ... ViewPoints: Genfit ploughs on with GFT505, but Phase II data far ... convinced.) How damaging was GFT505’s Phase II readout? Are doctors ... the 2019 timeframe)? Genfit’s GFT505 recently failed to hit its ... |